glp-1 mimetics Schematic Mechanism of Incretin in lowering the blood glucose Comparing Ozempic, Wegovy and Other

Medications are tools, not silver bullets

According to FAIR Health, prescriptions for GLP-1 drugs to treat overweight or obesity rose 587% from 2019 to 2024

A wave of VC-backed startups and PE-backed companies are rebranding compounding as a tech-enabled, consumer-first digital health service

They lower blood sugar, reduce blood pressure, improve cholesterol, protect the heart, and promote weight loss

New GLP-1-based obesity drugs like Ozempic and Wegovy are reshaping health care and society

Elimination pathways vary: exenatide and lixisenatide are cleared renally, whilst semaglutide, liraglutide and dulaglutide are broken down through protein degradation